Option Care Health (NASDAQ:OPCH) Delivers Impressive Q1, Full-Year Outlook Slightly Exceeds Expectations

Alternate site health provider Option Care Health (NASDAQ:OPCH) reported Q1 CY2025 results topping the market’s revenue expectations , with sales up 16.3% year on year to $1.33 billion. The company’s full-year revenue guidance of $5.5 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19% above analysts’ consensus estimates.

Is now the time to buy Option Care Health? Find out in our full research report .

Option Care Health (OPCH) Q1 CY2025 Highlights:

Company Overview

With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ:OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States.

Sales Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, Option Care Health’s 15.3% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.

Option Care Health (NASDAQ:OPCH) Delivers Impressive Q1, Full-Year Outlook Slightly Exceeds Expectations

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Option Care Health’s annualized revenue growth of 13.2% over the last two years is below its five-year trend, but we still think the results suggest healthy demand.

Option Care Health (NASDAQ:OPCH) Delivers Impressive Q1, Full-Year Outlook Slightly Exceeds Expectations

This quarter, Option Care Health reported year-on-year revenue growth of 16.3%, and its $1.33 billion of revenue exceeded Wall Street’s estimates by 6.1%.

Looking ahead, sell-side analysts expect revenue to grow 6.9% over the next 12 months, a deceleration versus the last two years. Still, this projection is above the sector average and implies the market is baking in some success for its newer products and services.

OK